Pet Longevity Industry Surges: Anti-Aging Drugs and GLP-1 Treatments Now Target Dogs and Cats

What Is the Pet Longevity Industry and Why Is It Growing So Fast?

The pet longevity industry represents a convergence of geroscience — the study of biological aging — with veterinary medicine. Companies like Loyal, which received the first-ever FDA acceptance of a lifespan extension drug for dogs in 2024, are pioneering treatments that aim not just to treat disease but to slow the aging process itself in companion animals. This sector has attracted hundreds of millions of dollars in venture capital investment in recent years.

Several factors are fueling this boom. Pet ownership has risen significantly worldwide, with the American Pet Products Association estimating that approximately 66% of US households own a pet. Owners increasingly view pets as family members and are willing to spend on advanced medical care. The global pet care market, which exceeds $300 billion annually according to industry analyses, provides a massive commercial foundation for longevity-focused startups and pharmaceutical companies alike.

How Are GLP-1 Drugs Being Used in Veterinary Medicine?

GLP-1 receptor agonists like semaglutide and tirzepatide have transformed human obesity and diabetes treatment, and veterinary researchers are now exploring similar approaches for pets. Obesity affects an estimated 59% of dogs and 61% of cats in the United States, according to the Association for Pet Obesity Prevention. Overweight pets face higher risks of diabetes, joint disease, cardiovascular problems, and shortened lifespans — closely mirroring the consequences seen in humans.

While no GLP-1 drug has yet received full regulatory approval specifically for pets, several companies are conducting clinical trials in dogs. The approach is scientifically plausible because GLP-1 receptors are conserved across mammalian species. However, veterinary pharmacologists caution that dosing, safety profiles, and long-term effects must be carefully studied in each species. The cost of these treatments, which can run over $1,000 per month in humans, also raises questions about accessibility and the ethics of premium pet medicine.

What Does the Dog Aging Project Tell Us About Canine Longevity?

The Dog Aging Project, launched in 2019 and funded in part by the National Institute on Aging, has enrolled more than 45,000 companion dogs in what researchers describe as the largest longitudinal study of aging in dogs ever conducted. The project collects data on genetics, environment, diet, and health outcomes to understand why some dogs live longer and healthier lives than others. A subset of dogs is participating in a clinical trial of low-dose rapamycin, an immunosuppressant drug that has extended lifespan in laboratory mice.

Dogs are considered an ideal model for aging research because they share our environments, develop many of the same age-related diseases, and age on a compressed timeline compared to humans. Findings from the project have already yielded insights into the relationship between body size and lifespan in dogs, and researchers hope the data will eventually translate into interventions that benefit both canine and human health. The intersection of pet longevity science and human geroscience is creating a unique research ecosystem where advances in one field directly inform the other.